Search
mirikizumab-mrkz (Omvoh)
Indications:
- treatment of moderate to severe ulcerative colitis in adults
Contraindications:
- hypersentitivity reactions
- avoid live virus vaccines
- active tuberculosis
-
Dosage:
- Prior to Treatment Initiation
- evaluate patients for tuberculosis infection
- obtain serum AST, serum ALT & serum bilirubin
- complete all age-appropriate vaccinations according to guidelines
- 300 mg via intravenous infusion over at least 30 minutes at Weeks 0, 4, & 8
- maintenance dosage is 200 mg via subcutaneous injection
- given as 2 consecutive injections of 100 mg each at Week 12, & every 4 weeks thereafter
* Intravenous Infusion: 300 mg/15 mL (20 mg/mL) solution in a single-dose vial
* Subcutaneous Injection: 100 mg/mL solution in a single-dose prefilled pen
Adverse effects:
- hepatotoxicity
- > 2%: upper respiratory tract infections, arthralgia
Mechanism of action:
- humanized IgG4 monoclonal antibody that selectively binds to the p19 subunit of human IL-23 cytokine & inhibits its interaction with the IL-23 receptor
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
pharmaceutical monoclonal antibody
References
- Brooks M
FDA Approves Mirikizumab for Ulcerative Colitis.
Medscape. October 27, 2023
https://www.medscape.com/viewarticle/997822
- D'Haens G, Dubinsky M, Kobayashi T et al
Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.
N Engl J Med 2023; 388:2444-2455, June 29
PMID: 37379135 Clinical Trial.
https://www.nejm.org/doi/full/10.1056/NEJMoa2207940
- HIGHLIGHTS OF PRESCRIBING INFORMATION
OMVOH (mirikizumab-mrkz) injection, for intravenous or subcutaneous use
https://pi.lilly.com/us/omvoh-uspi.pdf